Glypican-3-specific antibody and uses thereof
The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3.
1. An isolated and substantially purified polynucleotide encoding a single chain human anti-glypican-3 (GPC3) antibody fragment, wherein the single chain antibody fragment comprises a heavy chain variable region and light chain variable region, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region are selected from the group consisting of: (a) SEQ ID NO: 12 and SEQ ID NO: 17; (b) SEQ ID NO: 13 and SEQ ID NO: 18; (c) SEQ ID NO: 14 and SEQ ID NO: 19; and, (d) SEQ ID NO: 15 and SEQ ID NO: 20.
2. The isolated polynucleotide of claim 1 , comprising nucleic acid sequences that encode the heavy chain variable region and light chain variable region, wherein the heavy chain variable region-encoding nucleic acid sequence and the light chain variable region-encoding nucleic acid sequence are selected from the group consisting of: (a) SEQ ID NO: 52 and SEQ ID NO: 57; (b) SEQ ID NO: 53 and SEQ ID NO: 58; (c) SEQ ID NO: 54 and SEQ ID NO: 59; and, (d) SEQ ID NO: 55 and SEQ ID NO: 60.
3. An isolated and substantially purified vector comprising the isolated polynucleotide of claim 1 .
4. The vector of claim 3 , wherein the vector is a viral vector selected from the group consisting of an adenoviral vector, an adeno-associated virus vector, a retroviral vector, a poxvirus, a herpes simplex virus I, and a lentiviral vector.